Your session is about to expire
← Back to Search
Enoxaparin for Blood Clot Prevention (CRETE Trial)
CRETE Trial Summary
This trial is testing whether a blood thinner can help reduce the risk of a common complication in kids who need a central venous catheter.
CRETE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCRETE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CRETE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had surgery in the last week.You have had a serious injury in the past week.You are allergic to heparin or pork products.You have a catheter in your back for pain relief.You cannot participate if you had a central venous catheter inserted less than 24 hours ago.You have been diagnosed with heparin-induced thrombocytopenia (HIT) through laboratory tests.Your blood clotting test results show abnormal values, such as INR greater than 2.0, aPTT greater than 50 seconds, or platelet count less than 50,000 per microliter.I am between 36 weeks corrected gestational age and under 17 years old.I have had significant bleeding issues in the last 2 months.I am currently taking blood thinners, but not for a catheter.My kidney function is severely reduced.My central venous catheter is in my neck or upper thigh.You have been diagnosed with blood clots near the area where a medical device was inserted in the past 6 weeks.Restrictions on medical treatment or care.You have already participated in the CRETE Studies before.
- Group 1: Enoxaparin (Older Children Prophylactic)
- Group 2: Control (Older Children)
- Group 3: Enoxaparin (Infants Therapeutic High Anti-Xa Target)
- Group 4: Enoxaparin (Infants Therapeutic Low Anti-Xa Target)
- Group 5: Control (Infants)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What indications does Enoxaparin have the most evidence for?
"Enoxaparin is commonly used to treat acute chest syndrome. This medication can also be given to outpatients, angina, unstable, and ischemia patients."
Is this the first time Enoxaparin has been studied?
"Enoxaparin was first trialled at Oregon Health & Science University in 2014 and, to date, there have been 170 completed clinical studies. There are 24 more ongoing trials being conducted, many of which are based in Saint Louis, Missouri."
In how many locations are hospitals conducting this research?
"There are 16 clinical trial sites enrolling patients for this study. The locations are located in Saint Louis, Saint Petersburg and Rochester along with other locations 16 other locations. If you are considering participating in this trial, it is helpful to select the site closest to you to minimize travel demands."
Are there any open appointment times for this research program?
"This study, which was last updated on 11/3/2022 according to clinicaltrials.gov, is still recruiting patients. The posting for this trial went up on 5/11/2022."
Share this study with friends
Copy Link
Messenger